Suppliers / Takeda Pharmaceutical

Takeda Pharmaceutical

Japan 5 duplicate records merged Updated 9 July 2026

Takeda Pharmaceutical is an API manufacturer based in Japan. It appears in 28 regulatory filings across 2 regulators, without an active US DMF or CEP on file. Its filings concentrate with ARCSA (EC) and NMPA (CN). Its GMP standing is certified by MFDS (Korea).

0
active US DMFs
0
valid CEPs
0
registered plants
28
filings across 2 regulators

What they file, and where

Molecule Regulators Docs
Azilsartan Medoxomil SFDA (Saudi Arabia) 1
Candesartan Cilexetil SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
ARCSA (EC) 24 None
NMPA (CN) 4 None
MFDS (Korea) None 4

Questions about Takeda Pharmaceutical

Does Takeda Pharmaceutical hold a US DMF or a CEP?
No active US drug master file or valid CEP is on record for Takeda Pharmaceutical. It does have 28 filings with 2 regulators, so it is registered, just not with the two strong registers buyers usually screen on.
What does Takeda Pharmaceutical make?
2 molecules are on record against Takeda Pharmaceutical, including Azilsartan Medoxomil and Candesartan Cilexetil. Each links through to that molecule's full manufacturer list.
Which regulators recognise Takeda Pharmaceutical's GMP?
Current GMP certificates are on record from MFDS (Korea). GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Takeda Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates